InVivo Therapeutics Holdings Corp. NVIV Cash Flow

Invivo therapeutics holdings corp. (NVIV)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Cash flows from operating activities:
Net loss
-11,609	-11,830	-10,983	-11,479	-21,274	-23,423	-25,562	-31,737	-25,138	-26,745	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
52	57	60	65	67	91	83	189	300	395	518	528	537	548	574	616	652	684	711	726	735	752	0	0	0
Amortization of operating lease right-of-use assets
269	265	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on impairment of fixed assets
-	-	-	-	-	-48	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Derivatives loss
-	-	-	-	-	-11,400	-12,168	-13,260	-2,520	-2,267	-883	1,840	1,881	593	-243	3,684	-1,565	-10,804	-15,857	-16,443	-10,662	-376	0	0	0
Non-cash interest expense
-	-	-	-	-	-	5	5	5	5	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of asset
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issued to 401(k) plan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Common stock issued for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	477	0	0	0
Common stock issued to 401(k) plan
-	-	-	-	-	6	35	76	138	183	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issued to 401(k) plan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Share-based compensation expense
271	268	280	297	379	618	1,033	1,979	3,097	4,106	5,106	5,250	5,225	5,063	4,623	4,821	4,554	4,666	4,066	3,375	3,160	2,730	0	0	0
Non-cash investment (income) expense, net
-	-	-	-	0	-	-	-	-	-	-289	-6	-16	-98	0	0	0	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-61	-11	-10	-10	-180	0	0	0
Prepaid expenses
-351	-267	-966	-87	154	-77	1,026	589	43	89	62	-25	323	267	145	285	74	-888	-763	-670	-591	363	0	0	0
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	324	308	-4	-5	-3	-4	-5	-4	-4	0	0	0
Accounts payable
0	127	-458	-129	-240	-173	9	36	190	-23	713	318	599	489	-241	-394	-355	-48	86	361	89	-330	0	0	0
Operating lease liability
-241	-144	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses and other liabilities
-314	132	-417	-2,150	-1,439	-136	26	1,511	1,298	-144	62	642	423	1,471	104	96	-87	-279	558	-6	128	-248	0	0	0
Net cash used in operating activities
-10,678	-10,314	-11,412	-12,203	-11,977	-12,312	-13,426	-15,476	-17,236	-19,683	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from investing activities:
Purchases of marketable securities
-	-	-	-	-	-	-	-	-	8,256	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Sales of marketable securities
-	-	-	-	-	-	-	-	-	19,833	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Disposals of property and equipment
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-17,573	-	-15,192	-14,586	-14,003	-15,284	0	0	0
Purchases of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	18,916	0	0	0	-	-	-	-	-	-	-	-
Sales of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	12,515	0	0	0	-	-	-	-	-	-	-	-
Purchases of property and equipment
-	-	-	-	-	-	-	-	-	65	65	88	73	107	0	0	0	-	-	-	-	47	0	0	0
Net cash used in investing activities
-	-	-	-	-	-65	657	7,457	12,364	11,512	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Net cash (used in) provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-2	0	0	0
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	26	26	181	172	191	250	126	973	1,068	0	0	0	-	-	-	-
Proceeds from issuance of stock under ESPP
-	1	1	2	2	4	4	25	25	51	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,789	0	0	0	-	-	-	-
Principal payments on capital lease obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21	0	0	0
Repayment of loan payable
-	100	216	330	742	752	744	737	430	423	416	409	402	395	0	0	0	-	-	-	-	-	-	-	-
Repayment of loan payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Repayment of note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Repurchase of warrants
-	-	-	-	-	14	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock and warrants, net of commissions and issuance costs
0	-	-	-	-	16,511	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	29,905	33,347	33,347	33,352	14,480	10,865	11,026	25,540	14,618	0	0	0
Net cash (used in) provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38,949	-	19,694	18,847	28,640	14,765	0	0	0
Net cash (used in) provided by financing activities
6,688	268	-139	-207	13,392	15,880	15,775	15,758	2,063	-383	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in cash and cash equivalents and restricted cash
-4,002	-10,058	-11,551	-12,410	1,325	3,503	3,006	7,739	-2,809	-8,554	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	6,544	0	0	0	-	-	0	0	-	0	0	0
Supplemental disclosure of cash flow information and non-cash investing and financing activities:
Cash paid for interest
-	1	10	20	31	44	50	56	65	71	105	89	95	103	78	111	116	121	152	131	133	132	0	0	0
Fair value of warrants issued in connection with the 2020 Offering
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash issuance of common stock for warrants
-	-	-	-	-	287	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-use assets and lease liability recorded upon adoption of ASC 842
-	1,475	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of derivative warrant liability to additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-